Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AiCuris Anti-infective Cures AG
With
Medpace, Inc.
Enrolled patients with Mucocutaneous genital HSV, will be randomized to receive either AIC326 or Valacyclovir first and then will be crossed over to receive the opposite Intervention. The study will consist of two treatment periods of 28 days separated by a washout period of 28 days.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult, immunocompetent men and women in good health of any ethnic group
Seropositive for Herpes Simplex Virus Type 2 (HSV-2)
History of recurrent episodes (\>=4 to \<=9) of genital herpes for at least 12 months and willingness to obtain 4 swabs per day.
You may not be if
Present episode of genital herpes at time of randomization
Clinically relevant acute or chronic infections (excluding HSV-2)
Known intolerance to valacyclovir, acyclovir, or any component of the formulation
Documented HSV resistance to acyclovir, valacyclovir, famciclovir or penciclovir
